Iturri Lorea, Gilbert Cristéle, Espenon Julie, Bertho Annaïg, Potiron Sarah, Juchaux Marjorie, Prezado Yolanda
Institut Curie, Université Paris Sciences et Lettres (PSL), Centre National pour la recherche scientifique (CNRS) Unité mixte de recherche (UMR3347), Inserm U1021, Signalisation Radiobiologie et Cancer, Orsay, France.
Université Paris-Saclay, Centre National pour la recherche scientifique (CNRS) Unité mixte de recherche (UMR3347), Inserm U1021, Signalisation Radiobiologie et Cancer, Orsay, France.
Front Oncol. 2025 May 8;15:1493436. doi: 10.3389/fonc.2025.1493436. eCollection 2025.
Radioresistant and immunosuppressive tumors, such as glioblastoma multiforme (GBM), remain a challenge, as current clinical approaches-surgical resection and chemoradiation-do not yet provide effective treatment. (IT) has emerged as a powerful tool in ; however, phase III clinical trials in GBM have yielded unsuccessful results, likely due to its critical dependence on preexisting antitumor immunity. Given its immunomodulatory potential, radiotherapy (RT) could serve as a tool to induce tumor inflammation and enhance responsiveness to IT. However, the optimal radiation configuration required to achieve the critical level of tumor inflammation for IT success remains elusive. This study assessed the most effective dose fractionation scheme for maximizing immune cell infiltration into tumors.
Two orthotopic rat glioma models with differing vascularization and immunogenicity were irradiated with three dose fractionation schemes. Tumor immune cell populations were analyzed by flow cytometry.
A single high dose (25 Gy) or extreme hypofractionation is required to elicit a significant immune infiltration in tumors.
Using RT as an immune primer in GBM would require very high and toxic doses with conventional RT methods. While 25 Gy is used in conventional stereotactic radiosurgery, such a high dose is typically limited to small brain volumes. Novel approaches, such as FLASH-RT or minibeam RT, offer alternatives to mitigate toxicity while achieving the required doses.
诸如多形性胶质母细胞瘤(GBM)等放射抗性和免疫抑制性肿瘤仍然是一项挑战,因为当前的临床方法——手术切除和放化疗——尚未提供有效的治疗。免疫疗法(IT)已成为一种强大的工具;然而,GBM的III期临床试验结果并不成功,这可能是由于其严重依赖预先存在的抗肿瘤免疫力。鉴于其免疫调节潜力,放射疗法(RT)可作为诱导肿瘤炎症并增强对IT反应性的一种工具。然而,实现IT成功所需的肿瘤炎症临界水平所需的最佳放射配置仍然难以捉摸。本研究评估了使免疫细胞最大程度浸润肿瘤的最有效剂量分割方案。
用三种剂量分割方案对两种具有不同血管生成和免疫原性的原位大鼠胶质瘤模型进行照射。通过流式细胞术分析肿瘤免疫细胞群体。
需要单次高剂量(25 Gy)或极端低分割来引发肿瘤中的显著免疫浸润。
在GBM中使用RT作为免疫引发剂,采用传统RT方法需要非常高且有毒的剂量。虽然在传统立体定向放射外科手术中使用25 Gy,但如此高的剂量通常仅限于小的脑体积。诸如FLASH-RT或微束RT等新方法提供了在达到所需剂量的同时减轻毒性的替代方案。